/
GALT
$4.97-$0.02 (-0.40%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$328.6M
66M shares
52-week range
$2.03 – $7.13
58% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
36.77%
Hard to borrow
Price (6 mo)
Loading chart…
Change+$1.77
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $6.5M | $7.5M | $18.0M | $23.8M | $31.7M | $32.1M | $36.6M | $14.3M |
| Operating income | −$13.6M | −$13.4M | −$23.4M | −$30.2M | −$38.4M | −$38.1M | −$42.4M | −$20.1M |
| EBITDA | −$13.6M | −$13.2M | −$23.3M | −$30.0M | −$37.7M | −$38.2M | −$41.5M | −$23.5M |
| Net income | −$13.9M | −$13.3M | −$23.5M | −$30.5M | −$38.8M | −$41.1M | −$47.0M | −$30.8M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -0.35 | -0.39 | -0.41 | -0.52 | -0.65 | -0.74 | -0.76 | -0.48 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $180M | $-0.37 | $-0.37–$-0.37 | 1 |
| 2027 | $385M | $-0.33 | $-0.33–$-0.33 | 1 |
| 2028 | $572M | $-1.06 | $-1.06–$-1.06 | 1 |
| 2029 | $23M | $-0.91 | $-0.91–$-0.91 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
www.galectintherapeutics.com- Employees
- 9
- IPO / List date
- Sep 4, 2002
- HQ
- NORCROSS, GA
Held by traders on TradeandTell
No one on the platform currently holds GALT.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 147,900 | $412.6K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2012-03-23 | 1-for-6reverse |
Recent trades on TradeandTell
No one on the platform has traded GALT yet.
